BOVINE SERUM ALBUMIN MARKET ANALYSIS

Bovine Serum Albumin Market, By Form (Dry and Liquid), By Grade (Technical and Diagnostic Grade, Research/Reagent Grade, and Food Grade), By Application (In Vitro Diagnostics, Vaccine Production, Biochemical Assay, and Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Diagnostic Laboratories, Research Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In August 2023, Dyadic International announced positive third-party test results for its animal-free recombinant serum albumin, developed using the company's proprietary fungal-based microbial platforms. Dyadic successfully produced stable cell lines for recombinant bovine and human serum albumin, with initial tests showing the recombinant bovine albumin is structurally equivalent to the commercial animal-derived version.
In April 2022, Apotex Corporation launched a generic version of Abraxane, known as Paclitaxel protein-bound particles for injection (albumin-bound), in the U.S. .
In January 2022, Bio Products Laboratory (BPL) announced that China's National Medical Products Administration (NMPA) had approved the sale of ALBUMINEX 25% in China